300+ investors in your industry, stage, and region Get
Any industry
Community
Proptech
Biotech
Climate
Artificial Intelligence
Media (Entertainment)
Impact
FinTech
Marketplace
EdTech
Consumer
Agriculture (AgTech)
Web3
Clean Energy
B2B
Organic Food
Big Data
Video Games
Payments
Celebrity
Franchise
Mobile
Local
Social Network
Platforms
Crowdfunding
CleanTech
Film
Theatre
Life Science
Non Profit
Transportation
Gaming
Energy
Hardware
Health Care
Enterprise
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Publishing
Sporting Goods
Oil and Gas
Education
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Financial Services
Photography
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Blockchain
Legal
Android
Social Impact
Google
Construction
Sports
eSports
Enterprise Software
Email
Wellness
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Biotechnology
Medical Device
Wine and Spirits
Automotive
Social
InsurTech
SaaS
Software
Any country
Qatar
South Korea
Africa
Asia
LATAM
Europe
Oceania
Middle East
Ireland
Singapore
Indonesia
Spain
Saudi Arabia
Belarus
Belgium
Colombia
Denmark
Ecuador
Czech Republic
Estonia
Ghana
Ethiopia
Finland
Barbados
Italy
Jersey
Cayman Islands
Mali
Malaysia
Mauritius
Poland
Rwanda
Togo
Slovenia
San Marino
Tanzania
Thailand
Uruguay
Venezuela
Portugal
Azerbaijan
Namibia
Bolivia
Latvia
Cyprus
New Zealand
United States
Germany
Australia
India
United Kingdom
Canada
China
South Africa
Brazil
Japan
Sri Lanka
Vietnam
Argentina
Armenia
Austria
Bangladesh
Bahrain
Bulgaria
Bermuda
Chile
Cameroon
Switzerland
Belize
Costa Rica
Algeria
Georgia
Egypt
Hong Kong
Gibraltar
Faroe Islands
Greece
Croatia
France
Hungary
Kuwait
Israel
Lebanon
Cambodia
Kenya
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Morocco
Norway
Mexico
Panama
Malta
Peru
Philippines
Nicaragua
Pakistan
Russian Federation
Romania
Sweden
Serbia
Seychelles
Turkey
Puerto Rico
Sierra Leone
Senegal
Tunisia
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Taiwan
Ukraine
Zimbabwe
Bahamas
Guatemala
Iraq
Iceland
Nigeria
United Arab Emirates
Honduras
Isle of Man
Luxembourg
Oman
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology Angel Investors in United Kingdom (May 2026)

The most active angel investors investing in United Kingdom Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in United Kingdom Biotechnology startup companies. Find investors to raise a Pre-Seed, Seed or Series A round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Jonathan Milner
Angel
25 United Kingdom, United States, Canada Seed, Series A, Series B Biotechnology, Health Care, Medical $430k–$50M
Nadav Rosenberg
Angel
5 United Kingdom, Israel, Singapore Seed, Pre-Seed, Series A Biotechnology, Artificial Intelligence, Pharmaceutical $2M–$2M
Darrin Disley
Angel
4 United Kingdom Seed, Series A Biotechnology, Health Care, Big Data $430k–$3.7M
Jude Gomila
Angel
3 United States, United Kingdom, Canada Seed, Pre-Seed, Angel Software, Biotechnology, Information Technology $190k–$3.1M
Ian Hogarth
Angel
3 United Kingdom, United States, Germany Seed, Pre-Seed, Series A Software, E-Commerce, Health Care $123k–$12M
Peder Nielsen
Angel
3 United Kingdom Seed Biotechnology, Machine Learning
Stefano Bernardi
Angel
3 Italy, France, Norway Seed, Pre-Seed Software, Biotechnology, Cryptocurrency $2M–$2M
Milad Alucozai
Angel
3 United States, Canada, United Kingdom Seed, Series A, Pre-Seed Biotechnology, Health Care, Medical $91k–$60M
DrPano Kroko Churchill
Angel
3 United Kingdom Angel, Series A Health Care, Therapeutics, Biotechnology $150k–$430k
Ariel Poler
Angel
2 United States, Mexico, United Kingdom Seed, Series A, Angel Software, Social Media, Internet $1M–$7M
Gilad Engel
Angel
2 France, United Kingdom Seed, Pre-Seed Analytics, Biotechnology, Financial Services
Tim Dempsey
Angel
2 United Kingdom Seed, Series A Software, SaaS, Information Technology
Edward Lando
Angel
2 United States, France, United Kingdom Seed, Pre-Seed Software, Information Technology, Health Care $100k–$4.5M
Serge Chiaramonte
Angel
2 United Kingdom, United States, China Seed, Pre-Seed, Series A FinTech, Financial Services, E-Commerce $1.2M–$4.1M
Paul Wicks
Angel
2 United Kingdom Seed, Series A Real Time, Marketplace, Biotechnology
Pratima Aiyagari
Angel
2 United Kingdom, France, Croatia Pre-Seed, Seed, Series A Analytics, Information Technology, Software
Jon Oringer
Angel
2 United States, France, United Kingdom Seed, Pre-Seed Software, Information Technology, E-Commerce $80k–$9.3M
Patrick Pichette
Angel
2 United Kingdom, Germany, United States Seed, Series B, Series A Artificial Intelligence, Machine Learning, Software
Jim Mellon
Angel
2 United States, United Kingdom, Israel Series A, Seed Biotechnology, Health Care, Food and Beverage $503k–$20M
Inaki Berenguer
Angel
2 Spain, United States, United Kingdom Seed, Angel, Pre-Seed E-Commerce, FinTech, Enterprise Software $215k–$9M
Nadav Ben-Chanoch
Angel
2 United States, United Kingdom, France Seed, Pre-Seed Software, Information Technology, Health Care $100k–$5M
Charlie Songhurst
Angel
2 United States, United Kingdom, Germany Seed, Pre-Seed, Series A Software, Information Technology, Artificial Intelligence $360k–$18M
Ed Parkinson
Angel
2 United Kingdom Seed Software, Health Care, Life Science
Nicholas Edwards
Angel
2 United Kingdom Seed Medical, Health Care, Life Science
Chris Mairs
Angel
2 United Kingdom, United States Seed, Pre-Seed, Angel Software, FinTech, Financial Services $492k–$1M
Paul Forster
Angel
2 United Kingdom, Germany, Spain Seed, Series A, Pre-Seed Software, FinTech, Financial Services $750k–$9.9M
Mark Evans
Angel
2 United Kingdom, United States, The Netherlands Series A, Seed Software, E-Commerce, Health Care
Hugh Grant
Angel
2 United Kingdom Seed Biotechnology, Machine Learning
Jan Hruska
Angel
2 United Kingdom Seed Medical, Health Care, Life Science
Alex Payne
Angel
1 United States, Singapore Seed, Series A Data Visualization, Software, Food Processing $500k–$1.9M
Jim Warwick
Angel
1 United Kingdom Seed Life Science, Biotechnology
Jon Moulton
Angel
1 United Kingdom, Cyprus, Luxembourg Seed, Series A Financial Services, FinTech, Banking $1.8M–$8.5M
David Ebsworth
Angel
1 United Kingdom Seed, Post-IPO Equity Pharmaceutical, Biopharma, Health Care
Mark McCamish
Angel
1 United Kingdom Seed Medical, Biopharma, Biotechnology
Dave DeWalt
Angel
1 United States, Israel, United Kingdom Series A, Series C Cyber Security, Security, Network Security $9.5M–$11M
Bryan Meehan
Angel
1 United States, United Kingdom, Estonia Seed, Angel, Series A Packaging Services, Farming, Waste Management $2.7M–$6.2M
Richard Salvage
Angel
1 United Kingdom Seed CRM, Farming, Agriculture
Abdulaziz Alrashed
Angel
1 United Kingdom Seed Analytics, Biotechnology, Information Technology
Oliver Sexton
Angel
1 United Kingdom Seed, Pre-Seed Biotechnology, Health Care, Life Science
Sharaf Yamani
Angel
1 India, United Kingdom Seed Biotechnology, Software, Life Science
Brad Wilson
Angel
1 United Kingdom Seed Health Care, Biotechnology, Machine Learning
Margaret Georgiadis
Angel
1 United States, United Kingdom Seed, Series A, Series B Health Care, Apps, Wellness
Kristen Fortney
Angel
1 United Kingdom Series A Biopharma, Health Care, Therapeutics
Chris Gibson
Angel
1 United States, France, United Kingdom Series A, Seed Biotechnology, Pharmaceutical, Health Care
Silla Scheepens
Angel
1 United Kingdom Seed Biotechnology, Food Processing, Food and Beverage
Sami Mikati
Angel
1 India, United Kingdom Seed Biotechnology, Software, Life Science
David Rowan
Angel
1 United Kingdom, Croatia, United States Seed, Pre-Seed Software, Artificial Intelligence, Information Technology $1M–$2.4M
Martin Chavez
Angel
1 United States, United Kingdom Series A, Seed, Private Equity Health Care, Machine Learning, Biotechnology
Karl Wills
Angel
1 United Kingdom Seed CRM, Farming, Agriculture
Chris Paul
Angel
1 United States, France, Portugal Seed, Series A Food and Beverage, Sports, Health Care
Access all 139 angel investors in United Kingdom Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Jonathan Milner
Angel · Cambridge, Massachusetts, United States · 25 investments in United Kingdom Biotechnology startups

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Canada

Investor stats

  • Total investments: 44
  • Round size: Seed $430k–$10M; Series A $1.8M–$18M; Series B $1.8M–$50M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
  • Pencil Biosciences — Next Generation Genome Editing Tool
Show all investments...

Nadav Rosenberg
Angel · London, England, United Kingdom · 5 investments in United Kingdom Biotechnology startups

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Show more...

Investment focus

  • Industry: Biotechnology, Artificial Intelligence, Pharmaceutical
  • Stage:Seed, Pre-Seed, Series A
  • Geography: United Kingdom, Israel, Singapore

Investor stats

  • Total investments: 13
  • Round size: Pre-Seed $2M–$2M
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • thymia — Making mental health as objectively measurable as physical health.
  • Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
  • Loops — Loops is a no-code analytics platform that provides product and data teams with growth opportunities hidden in their data.
Show all investments...

Darrin Disley
Angel · Cambridge, Cambridgeshire, United Kingdom · 4 investments in United Kingdom Biotechnology startups

Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Big Data
  • Stage:Seed, Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 4
  • Round size: Seed $430k–$3.7M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Show all investments...

Jude Gomila
Angel · San Francisco, California, United States · 3 investments in United Kingdom Biotechnology startups

Jude Gomila is currently CEO and Founder of the startup Golden.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Pre-Seed, Angel
  • Geography: United States, United Kingdom, Canada

Investor stats

  • Total investments: 50
  • Round size: Seed $1.2M–$3.1M; Angel $190k–$1.3M; Pre-Seed $1.2M–$2M
  • Lead/follow: 4% lead, 96% follow

Portfolio highlights

  • Parcha AI — Parcha is an AI-powered enterprise software that enables businesses to automate their scale compliance and operations.
  • Monitaur — Reduce operational overhead, improve security, optimize performance, and deliver amazing customer experiences with our end-to-end, hybrid observability & APM platform built for decentralized apps and infrastructure.
  • Gradia Health — Gradia is an integrated, concierge care platform designed for clinics to support patients with chronic conditions.
Show all investments...

Ian Hogarth
Angel · London, England, United Kingdom · 3 investments in United Kingdom Biotechnology startups

Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.

Show more...

Investment focus

  • Industry: Software, E-Commerce, Health Care
  • Stage:Seed, Pre-Seed, Series A
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 40
  • Round size: Seed $1.5M–$12M; Pre-Seed $123k–$1.4M
  • Lead/follow: 5% lead, 95% follow

Portfolio highlights

  • Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
  • The Garden — The Garden is an online media company.
  • Condense — Live-streamed volumetric video into game engines
Show all investments...

Peder Nielsen
Angel · Copenhagen, Hovedstaden, Denmark · 3 investments in United Kingdom Biotechnology startups

Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund

Show more...

Investment focus

  • Industry: Biotechnology, Machine Learning
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 3
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Show all investments...

Stefano Bernardi
Angel · San Francisco, California, United States · 3 investments in United Kingdom Biotechnology startups

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Cryptocurrency
  • Stage:Seed, Pre-Seed
  • Geography: Italy, France, Norway

Investor stats

  • Total investments: 13
  • Round size: Pre-Seed $2M–$2M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
  • Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
  • CaSRevolution — A novel disease-modifying approach against neurodegeneration
Show all investments...

Milad Alucozai
Angel · San Francisco, California, United States · 3 investments in United Kingdom Biotechnology startups

Dr. Milad Alucozai is an Afghan-American neuroscientist, entrepreneur, biotech executive, and global investor with nearly two decades of experience in deep tech, primarily in life sciences. He pushes the boundaries of bioengineering and computational advancements, integrating machine learning and artificial intelligence into biology and medicine.With a strong commitment to commercializing transformative technologies and fostering startup ecosystems worldwide, he is a thought leader and formal mentor for entrepreneurs through organizations like Creative Destruction Lab and the Wyss Institute at Harvard Medical School.Currently, Milad is the head of Bio and Deep Tech at BoxOne Ventures, where he spearheads the firm’s investments in early-stage companies with breakthrough scientific ideas. With nearly 80 early-stage investments, they are recognized as one of North America’s most active venture firms. He is also a Venture Partner at Entrepreneur First, a global fund that has built over 500 companies from scratch with an enterprise value of $10bn. He supports founders with strategy, scaling, business development, securing growth capital, and leadership training, often being their first investor and guiding them from startup inception to IPOs or acquisitions.He started his career in translational neuroscience and multiphysics laboratories before transitioning into founding roles at biotech startups. He is part of the founding team at Mekonos, a San Francisco-based company creating a proprietary cell-engineering platform to support the future of cell and gene therapies. He was also part of the founding team at Corstem, which specialized in machine learning and artificial intelligence software and was later acquired by Circle Cardiovascular, a platform in over 1000 hospitals and more than 40 countries. At Accenture, Milad directed teams of data scientists, designers, and engineers in developing artificial intelligence platforms for global pharmaceutical companies and hospital networks.Milad serves as a Fellow in Healthcare Engineering at the Regenstrief Center. In 2020, he served as an External Advisor to AstraZeneca. He was recognized as a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed his master’s in Immunology and earned his doctorate from the Richard M. Fairbanks School of Public Health.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United States, Canada, United Kingdom

Investor stats

  • Total investments: 47
  • Round size: Seed $91k–$4.5M; Pre-Seed $107k–$1.4M; Series A $25M–$60M
  • Lead/follow: 9% lead, 91% follow

Portfolio highlights

  • Arpeggio Bio — Arpeggio Biosciences leverages state of the art sequencing approaches coupled with powerful machine learning to uncover novel insights into a compound's biological mechanism of action.The company is diverse set of molecular biologists, computer scientists, and biotechnology enthusiasts passionate about understanding where, why, and howtherapeutics work.
  • Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
  • Eigen Therapeutics — Eigen Therapeutics is a biotechnology company developing combination therapeutics for cancer. The company is in the research and development of synergistic therapies that improve efficacy while reducing the toxicity of small molecule therapies and immunotherapies, enabling physicians to get access to novel drugs in areas of unmet medical needs.
Show all investments...

DrPano Kroko Churchill
Angel · Seattle, Washington, United States · 3 investments in United Kingdom Biotechnology startups

Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com

Show more...

Investment focus

  • Industry: Health Care, Therapeutics, Biotechnology
  • Stage:Angel, Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 3
  • Round size: Angel $150k–$430k
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Show all investments...

Ariel Poler
Angel · San Francisco, California, United States · 2 investments in United Kingdom Biotechnology startups

Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.

Show more...

Investment focus

  • Industry: Software, Social Media, Internet
  • Stage:Seed, Series A, Angel
  • Geography: United States, Mexico, United Kingdom

Investor stats

  • Total investments: 44
  • Round size: Seed $1.1M–$7M; Angel $1M–$1.7M; Series A $2.6M–$5M
  • Lead/follow: 5% lead, 95% follow

Portfolio highlights

  • Reloadly — Reloadly is the #1 mobile top-up platform when it comes to developer-friendly technology. With our API and a few lines of code, you can easily integrate mobile top-up features into your website or mobile app.
  • Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
  • humm — humm harnesses cutting-edge neuroscience into products that allow people to learn faster and perform better.humm is working to bring the incredible results of neuroscience research out of the lab and into non-invasive wearables that improve the quality of life for everyday people. Our first product is a clinically validated patch that you wearfor 15 minutes to get up to 90 minutes of improved working memory, by gently stimulating the signals in the part of the brain that controls your executive thinking. humm improves your ability to learn and be at your best, allowing people to reconnect with the joy of learning and challenge themselves to continue growing at any stage of life, whether it's for work or personal enjoyment!
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Gilad Engel
Angel · 2 investments in United Kingdom Biotechnology startups

Gilad Engel - Partner @ Target Global

Show more...

Investment focus

  • Industry: Analytics, Biotechnology, Financial Services
  • Stage:Seed, Pre-Seed
  • Geography: France, United Kingdom

Investor stats

  • Total investments: 3
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Show all investments...

Tim Dempsey
Angel · 2 investments in United Kingdom Biotechnology startups

Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.

Show more...

Investment focus

  • Industry: Software, SaaS, Information Technology
  • Stage:Seed, Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 16
  • Lead/follow: 6% lead, 94% follow

Portfolio highlights

  • Lunio — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
  • Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
  • PPC Protect — Drive performance marketing efficiency by cutting out invalid traffic across all paid marketing channels. Reach more users with the same ad spend.
Show all investments...

Edward Lando
Angel · San Francisco, California, United States · 2 investments in United Kingdom Biotechnology startups, 17 in the past 12 months

Edward Lando is the Managing Partner at Pareto Holdings.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Pre-Seed
  • Geography: United States, France, United Kingdom

Investor stats

  • Total investments: 221
  • Round size: Seed $321k–$4.5M; Pre-Seed $100k–$1.9M
  • Lead/follow: 1% lead, 99% follow

Portfolio highlights

  • micro1 — We help companies hire and manage the best software engineers easily.
  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show all investments...

Serge Chiaramonte
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Serge Chiaramonte

Show more...

Investment focus

  • Industry: FinTech, Financial Services, E-Commerce
  • Stage:Seed, Pre-Seed, Series A
  • Geography: United Kingdom, United States, China

Investor stats

  • Total investments: 47
  • Round size: Seed $1.2M–$4.1M; Series A $2.7M–$3.7M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Trezy — Trezy is smart & simple software the helps you manage your business with real-time finance insights & automated cash-flow forecasting.
  • Basket — Basket lets you keep track of things you want to buy, automatically finding the best prices, saving you time and money. Say hello to your new shopping companion.
  • Klasha — At Klasha, we're simplifying borderless payments for commerce in Africa. We help merchants worldwide sell online to Africa and receive payments in local African currencies while enjoying super fast last-mile delivery to customers across the continent.
Show all investments...

Paul Wicks
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Paul is a neuropsychologist and expert in digital health, clinical trials, and patient centricity. For 13 years he led the R&D team at PatientsLikeMe, an online community for over 700,000 people living with medical conditions. Specialising in clinical research using the Internet, Paul shaped the scientific validity of the platform in generatinginsights from patient-generated health data, leading to over 110 studies including a patient-driven observational trial of lithium in ALS, numerous patient-reported outcome measures, a “dose-response” curve for the benefits of friendship between patients, and methods for patient-centered and virtual clinical trial designs.He sits on the editorial boards of the BMJ, BMC Medicine, JMIR, Digital Biomarkers and The Patient. Prior to joining PatientsLikeMe, Paul worked at the Institute of Psychiatry (King’s College London) studying cognition and neuroimaging in ALS, with a postdoc in psychological consequences of Parkinson’s disease.His work has been profiled by the BBC, NPR, CNN, BBC Radio 4, the Wall Street Journal, and the New York Times. In 2011 he was awarded MIT Technology Review’s TR35 “Humanitarian of the Year” award, recognized as a TED Fellow in 2012, and joined the inaugural FLIER Program at the Academy of Medical Sciences in 2019.

Show more...

Investment focus

  • Industry: Real Time, Marketplace, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Sano Genetics — The future of precision medicine is here. Deep dive into your DNA & contribute to the latest research opportunities. Discover Sano Genetics.
Show all investments...

Pratima Aiyagari
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.

Show more...

Investment focus

  • Industry: Analytics, Information Technology, Software
  • Stage:Pre-Seed, Seed, Series A
  • Geography: United Kingdom, France, Croatia

Investor stats

  • Total investments: 8
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
  • NetBird — Wiretrustee is an open-source VPN platform built on top of WireGuard® making it easy to create secure private networks for your organization or home. It requires zero configuration effort leaving behind the hassle of opening ports, complex firewall rules, VPN gateways, and so forth.
  • Treblle — Treblle is a lightweight SDK that helps Engineering and DevOps teams build, ship & maintain REST based APIs faster
Show all investments...

Jon Oringer
Angel · Miami, Florida, United States · 2 investments in United Kingdom Biotechnology startups

Jon Oringer is the founder and chairman of Shutterstock.

Show more...

Investment focus

  • Industry: Software, Information Technology, E-Commerce
  • Stage:Seed, Pre-Seed
  • Geography: United States, France, United Kingdom

Investor stats

  • Total investments: 106
  • Round size: Seed $326k–$9.3M; Pre-Seed $80k–$3.2M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
  • Zamp — We give you freedom from sales tax! Eliminate the need to learn, manage or touch any part of the sales tax compliance process.
  • NewHomesMate (formerly Propertymate) — Find, compare and buy a new construction home - all in one place.
Show all investments...

Patrick Pichette
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Patrick Pichette currently Board Member at LightSpeed and Twitter. He is a former Google's chief financial officer, where he started in June of 2008. He has nearly 20 years of experience in financial operations and management in the telecommunications sector, including seven years at Bell Canada, which he joined in 2001 as executive vicepresident of planning and performance management.During his time at Bell Canada, he held various executive positions, including CFO from 2002 until the end of 2003, and was instrumental in the management of the most extensive communications network in Canada and its ongoing migration to a new national IP-based infrastructure.Prior to joining Bell Canada, Patrick was a partner at McKinsey & Company, where he was a lead member of McKinsey's North American Telecom Practice. He also served as vice president and chief financial officer of Call-Net Enterprises, a Canadian telecommunications company.Patrick earned a bachelor's degree in business administration from UniversitA© du Quebec A  MontrA©al. He holds a master's degree in philosophy, politics, and economics from Oxford University, where he attended as a Rhodes Scholar. He also serves on the board of Engineers Without Borders (Canada).

Show more...

Investment focus

  • Industry: Artificial Intelligence, Machine Learning, Software
  • Stage:Seed, Series B, Series A
  • Geography: United Kingdom, Germany, United States

Investor stats

  • Total investments: 19
  • Lead/follow: 6% lead, 94% follow

Portfolio highlights

  • Apheris — Build ML-powered products using data that spans organizational or geographical boundaries, while ensuring compliance with regulation.
  • Unlikely AI — We are pioneering safe, trustworthy and powerful artificial intelligence
  • Vay — Vay is a leading teledriving company that aims to launch a unique, affordable, and sustainable door-to-door mobility service.
Show all investments...

Jim Mellon
Angel · 2 investments in United Kingdom Biotechnology startups

Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Food and Beverage
  • Stage:Series A, Seed
  • Geography: United States, United Kingdom, Israel

Investor stats

  • Total investments: 26
  • Round size: Seed $503k–$20M; Series A $2.8M–$4.3M
  • Lead/follow: 42% lead, 58% follow

Portfolio highlights

  • Amy — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
  • Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
  • The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Show all investments...

Inaki Berenguer
Angel · New York, New York, United States · 2 investments in United Kingdom Biotechnology startups

Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.

Show more...

Investment focus

  • Industry: E-Commerce, FinTech, Enterprise Software
  • Stage:Seed, Angel, Pre-Seed
  • Geography: Spain, United States, United Kingdom

Investor stats

  • Total investments: 17
  • Round size: Seed $215k–$9M; Angel $236k–$500k
  • Lead/follow: 12% lead, 88% follow

Portfolio highlights

  • Paack — Find the ideal delivery solution to integrate to your e-commerce. We adapt to your retail, offering your customer an amazing delivery experience.
  • Libera Bio — Libera Bio is a biopharmaceutical company devoted to the development of a new class of therapeutics to address unmet medical needs in cancer
  • Mable (Neurolytic Healthcare) — Neurolytic Healthcare provides personalized medicine for neurological conditions. Neurolytic Healthcare collects and extracts insights from a combination of genetic and biomarker data to enhance diagnosis and help clinicians decide on optimal treatment strategies for neurological conditions.The company delivers digitally and genomically-drivenmedical devices to improve the current treatment of migraine and other neurological disorders, including a diagnostic support tool, pharmacogenetic test, and a mobile app for migraine event prediction.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Nadav Ben-Chanoch
Angel · Miami, Florida, United States · 2 investments in United Kingdom Biotechnology startups, 12 in the past 12 months

Nadav Ben-Chanoch - Partner @ Pareto Holdings

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Pre-Seed
  • Geography: United States, United Kingdom, France

Investor stats

  • Total investments: 147
  • Round size: Seed $120k–$5M; Pre-Seed $100k–$1.9M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Swaap — We build the market-neutral AMM protocol.
  • micro1 — We help companies hire and manage the best software engineers easily.
  • Skedway — Every work experience should be great! Skedway is the complete platform to optimize the hybrid work experience.
Show all investments...

Charlie Songhurst
Angel · Greater Seattle Area, Washington, United States · 2 investments in United Kingdom Biotechnology startups, 20 in the past 12 months

Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Pre-Seed, Series A
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 137
  • Round size: Seed $1M–$6.4M; Pre-Seed $360k–$3.8M; Series A $2.5M–$18M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Hubflo — Hubflo is building an all-in-one work OS to help small businesses manage their business. Instead of having 10 complicated and expensive pieces of software, Hubflo offers SMB everything they need to run their business (CRM, projects, invoicing, expenses...) in a single comprehensive, simple and affordable platform.
  • Story Protocol — Story Protocol is building open IP infrastructure to grow the creativity of the internet era.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Show all investments...

Ed Parkinson
Angel · 2 investments in United Kingdom Biotechnology startups

Ed Parkinson

Show more...

Investment focus

  • Industry: Software, Health Care, Life Science
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: no public data

Portfolio highlights

  • Antiverse — Designing biologics for 100 challenging targets
Show all investments...

Nicholas Edwards
Angel · Oxford, Oxfordshire, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Nick serves as the Chairman of Prescient’s Board of Directors. He holds a degree in physiological sciences from The Queen’s College, University of Oxford, and completed his training in clinical medicine (BM, BCh) at Green College (now Green Templeton College), University of Oxford. Nick practiced in the areas of cardiology and general surgerybefore joining Andersen Consulting (now known as Accenture), eventually becoming the global leader of Accenture’s pharmaceutical R&D business during his 18-year tenure. In 2005, he founded Kinapse to provide consulting and outsourcing services to the pharmaceutical industry. Nick served as Kinapse’s Chairman until the company was sold to HgCapital in early 2016.

Show more...

Investment focus

  • Industry: Medical, Health Care, Life Science
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Show all investments...

Chris Mairs
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Chris Mairs - Venture Partner @ Entrepreneur First

Show more...

Investment focus

  • Industry: Software, FinTech, Financial Services
  • Stage:Seed, Pre-Seed, Angel
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 17
  • Round size: Seed $492k–$1M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Pathway — LLM-enabled financial research at the speed of thought.
  • Statement — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
  • Borderless — Borderless is a workforce migration platform.It offers automation solutions that focuses on all aspects of hiring and onboarding of foreign workers, including recruitment, immigration, relocation, and compliance.
Show all investments...

Paul Forster
Angel · 2 investments in United Kingdom Biotechnology startups, 7 in the past 12 months

Paul Forster

Show more...

Investment focus

  • Industry: Software, FinTech, Financial Services
  • Stage:Seed, Series A, Pre-Seed
  • Geography: United Kingdom, Germany, Spain

Investor stats

  • Total investments: 57
  • Round size: Seed $750k–$4.5M; Pre-Seed $1M–$1.6M; Series A $2.9M–$9.9M
  • Lead/follow: 2% lead, 98% follow

Portfolio highlights

  • Outverse — A community platform that's easier to use, better organised and designed for real interaction.
  • CultureAI — Measure and improve human cyber risks and security behaviours to prevent security incidents. Go beyond security awareness training, start your free trial today.
  • finway — finway provides financial guidence to SMEs, plan & control all expenses and budgets in one tool.
Show all investments...

Mark Evans
Angel · London, England, United Kingdom · 2 investments in United Kingdom Biotechnology startups

Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.

Show more...

Investment focus

  • Industry: Software, E-Commerce, Health Care
  • Stage:Series A, Seed
  • Geography: United Kingdom, United States, The Netherlands

Investor stats

  • Total investments: 37
  • Lead/follow: no public data

Portfolio highlights

  • ONI — ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers. The Nanoimager, the world's first benchtop sized super-resolution microscope, delivers a step change in usability and precision. This, together with our next-generation consumable products will empower academicresearchers, clinicians and scientists to on a path to discovery.The microscope offers easy access to a range of super-resolution techniques including dSTORM and PALM, as well as smFRET, single-particle tracking and confocal.The company's achievements have been recognised by FastTrack100 who named ONI on their 2018 list of 10 Disruptors to Watch and ONI won Best Business Start-up at the 2018 IOP Awards. More and more life science researchers and pharma companies are taking an interest in ONI and it now has customers using its products in leading laboratories across the globe, including the Universities of Oxford, Cambridge and Harvard.ONI has a restless enthusiasm to make the world a better place. Our ambition is to bring super-resolution fluorescence imaging to a new community of researchers and we are removing barriers to make science more effective, accessible and affordable. Our vision is to accelerate scientific discovery and fight disease by enabling everyone to visualize, understand and share the microscopic details of life.
  • Ufonia — Ufonia is replacing routine patient healthcare interactions with next-generation automated phone calls.
  • Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Show all investments...

Hugh Grant
Angel · Saint Louis, Missouri, United States · 2 investments in United Kingdom Biotechnology startups

Hugh Grant is President and Chief Executive Officer at Monsanto.

Show more...

Investment focus

  • Industry: Biotechnology, Machine Learning
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Show all investments...

Jan Hruska
Angel · 2 investments in United Kingdom Biotechnology startups

Jan Hruska

Show more...

Investment focus

  • Industry: Medical, Health Care, Life Science
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Oxford Medical Products — Oxford Medical Products is a UK-based biotechnology start-up revolutionising the weight-loss treatment space with its hydrogel-based technology.
Show all investments...

Alex Payne
Angel · Portland, Oregon, United States · 1 investments in United Kingdom Biotechnology startups

Alex Payne the co-founder and CTO of BankSimple, an online banking disruption startup. Previously he was an Engineer at Twitter and led the API team.

Show more...

Investment focus

  • Industry: Data Visualization, Software, Food Processing
  • Stage:Seed, Series A
  • Geography: United States, Singapore

Investor stats

  • Total investments: 6
  • Round size: Seed $500k–$1.9M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Shiok Meats — Delicious, healthy & cell-based seafood from Shiok Meats. Get variety of cultivated meat, cultivated seafood, cell cultured meat & Lab Meats in Singapore.
  • Extracellular — Extracellular is a scale-up and development partner, channelling biology, digitalisation and biomanufacturing expertise to accelerate the potential of cultivated meat.
  • Next Level Burger — Order burgers, shakes, chik'n, fries and more from America's first 100% plant-based burger joint chain. All organic veggies, always non-GMO. Vegan menu options for all!
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Jim Warwick
Angel · Cambridge, Cambridgeshire, United Kingdom · 1 investments in United Kingdom Biotechnology startups

Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.

Show more...

Investment focus

  • Industry: Life Science, Biotechnology
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 50% lead, 50% follow

Portfolio highlights

  • Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
Show all investments...

Jon Moulton
Angel · 1 investments in United Kingdom Biotechnology startups

Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.

Show more...

Investment focus

  • Industry: Financial Services, FinTech, Banking
  • Stage:Seed, Series A
  • Geography: United Kingdom, Cyprus, Luxembourg

Investor stats

  • Total investments: 18
  • Round size: Seed $1.8M–$3.6M; Series A $4.9M–$8.5M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Pockit — Open a prepaid account in 3 minutes online or in-app, get your contactless prepaid card in 2 working days with no credit check.
  • Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
  • Hellas Direct — Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and artificial intelligence. The Cyprus-based company is backed by a roster of leading investors, including Portag3, IFC (a member of the World Bank), Endeavor Catalyst, former Goldman Sachs economist Lord O’Neill and private equity veteran JonMoulton. Modelling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence.
Show all investments...

David Ebsworth
Angel · Zürich, Zurich, Switzerland · 1 investments in United Kingdom Biotechnology startups

Dr. Ebsworth served as Chief Executive Officer of Vifor Pharma, based in Zürich, the specialty pharma division of Galenica AG Group, a pharmaceutical wholesaler and retailer, and as a member of Galenica’s Executive Committee. In 2012, Dr. Ebsworth was also named as Chief Executive Officer of Galenica and as Chairman of Galenica’s ExecutiveCommittee, positions he held until August 2014. Dr. Ebsworth received a PhD in industrial relations from the University of Surrey.

Show more...

Investment focus

  • Industry: Pharmaceutical, Biopharma, Health Care
  • Stage:Seed, Post-IPO Equity
  • Geography: United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Small Pharma — Small Pharma is a biotechnology company researching and developing short-duration psychedelics with therapy for under-served mental health conditions.
  • Verona Pharma — Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.
Show all investments...

Mark McCamish
Angel · Ventura, California, United States · 1 investments in United Kingdom Biotechnology startups

Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University

Show more...

Investment focus

  • Industry: Medical, Biopharma, Biotechnology
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
Show all investments...

Dave DeWalt
Angel · San Francisco, California, United States · 1 investments in United Kingdom Biotechnology startups

David G. DeWalt is the Founder and Managing Director of Dave DeWalt. He joined AllegisCyber Capital as a Managing Director in 2017. Dave is a renowned cybersecurity executive, having taken cyber industry leader FireEye public (Chairman & CEO) and served as the CEO of both McAfee and Documentum.He is a member or leader of six boards ofdirectors, including ForgeRock, ForeScout, Phantom Cyber, and OPTIV, and serves as the Vice Chairman of Delta Airlines. Dave consults regularly with government, industry players, and the corporate Board of Directors on matters related to cybersecurity policy, technology, and strategy.He holds a B.S. in computer science from the University of Delaware.

Show more...

Investment focus

  • Industry: Cyber Security, Security, Network Security
  • Stage:Series A, Series C
  • Geography: United States, Israel, United Kingdom

Investor stats

  • Total investments: 19
  • Round size: Series A $9.5M–$11M
  • Lead/follow: 74% lead, 26% follow

Portfolio highlights

  • Callsign — Marking a new era in passive authentication, fraud prevention and intelligence. We make digital identity simple and more secure.
  • RapidSOS — RapidSOS securely links life-saving data from connected devices, apps and sensors to safety agents, 911 and first responders globally.
  • Instant Channel — Instant Channel, Inc. is an advertising and marketing company that provides email marketing and communications services in the State of California.
Show all investments...

Bryan Meehan
Angel · San Francisco, California, United States · 1 investments in United Kingdom Biotechnology startups

Bryan Meehan CEO at Blue Bottle Coffee. Previously, I co-founded Nude Skincare (acquired by LVMH) and Fresh & Wild in London (acquired by Whole Foods).I'm an advocate of socially responsible investing and co-founded Greenmont Capital, a venture firm focused on investing in people who are primarily interested in creating environmentallyfriendly products. Investments include IZZE soda line and Mary's Gone Crackers. I get very excited about great founders and have recently invested in Slack, Hampton Creek, and of course, Blue Bottle Coffee where I spend most of my time working with James Freeman and the Blue Bottle team. I'm also a very active real estate investor.I grew up in Dublin. Since, I've lived in London, Boston and San Francisco. I love music, hiking, travel, art, organic food and coffee. I'm on the Board of Trustees at De Young and Legion of Honor museums in San Francisco. I hate GMOs and campaigning hard to have food properly labelled.

Show more...

Investment focus

  • Industry: Packaging Services, Farming, Waste Management
  • Stage:Seed, Angel, Series A
  • Geography: United States, United Kingdom, Estonia

Investor stats

  • Total investments: 9
  • Round size: Seed $2.7M–$6.2M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Shellworks — Reimaging nature's packaging with beautifully sustainable, truly compostable alternatives to plastic for cosmetics and beauty products.
  • Woola — A sustainable alternative to bubble wrap: protective e-commerce packaging made of leftover wool. Lightweight. Compostable. Customisable.
  • 8B Education Investments — 8B African Education Investments helps African students succeed at global universities with tools, resources, and world-class support to master every step of their educational journey.
Show all investments...

Richard Salvage
Angel · 1 investments in United Kingdom Biotechnology startups

Richard Salvage

Show more...

Investment focus

  • Industry: CRM, Farming, Agriculture
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: no public data

Portfolio highlights

  • Bionema — Leading UK biopesticides technology developer, specialising in organic chemical-free, biological crop protection for safe and sustainable agriculture.
Show all investments...

Abdulaziz Alrashed
Angel · 1 investments in United Kingdom Biotechnology startups

Abdulaziz Alrashed.

Show more...

Investment focus

  • Industry: Analytics, Biotechnology, Information Technology
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: no public data

Portfolio highlights

  • Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
Show all investments...

Oliver Sexton
Angel · London, England, United Kingdom · 1 investments in United Kingdom Biotechnology startups

Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Life Science
  • Stage:Seed, Pre-Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 9
  • Lead/follow: 30% lead, 70% follow

Portfolio highlights

  • MicrofluidX — Delivering the next generation of automated cell and gene therapy manufacturing platforms to bring precision medicine to patients
  • Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
  • Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Show all investments...

Sharaf Yamani
Angel · London, England, United Kingdom · 1 investments in United Kingdom Biotechnology startups

Sharaf Yamani - Managing Director @ Windlesham Advisors

Show more...

Investment focus

  • Industry: Biotechnology, Software, Life Science
  • Stage:Seed
  • Geography: India, United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
  • Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Brad Wilson
Angel · Plymouth Meeting, Pennsylvania, United States · 1 investments in United Kingdom Biotechnology startups

Brad Wilson Global Product Director at GlaxoSmithKline.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Machine Learning
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • OxCan — Enabling curative cancer treatment through early detection
Show all investments...

Margaret Georgiadis
Angel · San Francisco, California, United States · 1 investments in United Kingdom Biotechnology startups

Margaret Georgiadis currently works as CEO-Partner and Co-Founder for Flagship Pioneering. She previously worked at General Catalyst as Endurance Partner In Residence. Margaret Georgiadis attended Harvard University

Show more...

Investment focus

  • Industry: Health Care, Apps, Wellness
  • Stage:Seed, Series A, Series B
  • Geography: United States, United Kingdom

Investor stats

  • Total investments: 10
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • OneRoof — OneRoof is an app that helps meet people with similar interests living in your building and build new friendships. Communication should go further than a nod in the elevator.
  • ShareWell — Struggling with mental health issues? ShareWell provides online peer support, a proven mental health alternative for therapy. Get group support when you need it.
  • Bridge Money — The path towards upward economic mobility.
Show all investments...

Kristen Fortney
Angel · San Francisco, California, United States · 1 investments in United Kingdom Biotechnology startups

Kristen Fortney - CEO & Co-Founder @ BIOAGE LABS

Show more...

Investment focus

  • Industry: Biopharma, Health Care, Therapeutics
  • Stage:Series A
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
Show all investments...

Chris Gibson
Angel · Salt Lake City, Utah, United States · 1 investments in United Kingdom Biotechnology startups

Chris Gibson is the Co-Founder and CEO of Recursion (Recursion Pharmaceuticals). He previously worked at Cure HHT as a Member Board of Directors. Chris Gibson attended the University of Utah.

Show more...

Investment focus

  • Industry: Biotechnology, Pharmaceutical, Health Care
  • Stage:Series A, Seed
  • Geography: United States, France, United Kingdom

Investor stats

  • Total investments: 8
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
  • Amenities — Amenities is the healthcare industry's leading Digital Front Door and patient loyalty platform. We help healthcare providers to acquire new patients and upgrade them to members. Our all-in-one patient app works with most modern EMRs to: 1) register new users into a full EMR account in <30 seconds with full identity verification and noduplicates, 2) help those patients find care options and book appointments with simple, conversion-optimized workflows, 3) seamlessly integrates key patient portal and 3rd party functions (i.e., video visits, secure messaging, test results, and billing), and 4) upgrade patients to members with custom experiences and services offerings (i.e., for Medicare Advantage, concierge memberships, direct-to-employer, or direct primary care patients)
  • 64x Bio — 64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery.The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specificfocus on those used for cell and gene therapies.
Show all investments...

Silla Scheepens
Angel · 1 investments in United Kingdom Biotechnology startups

Silla Scheepens of Future Food Fund.

Show more...

Investment focus

  • Industry: Biotechnology, Food Processing, Food and Beverage
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: no public data

Portfolio highlights

  • Extracellular — Extracellular is a scale-up and development partner, channelling biology, digitalisation and biomanufacturing expertise to accelerate the potential of cultivated meat.
Show all investments...

Sami Mikati
Angel · 1 investments in United Kingdom Biotechnology startups

Sami Mikati is a Director of Synthace Ltd. Investor and commercial executive with deep experience and network across energy and engineering industries in Europe, the Middle East and Africa.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Life Science
  • Stage:Seed
  • Geography: India, United Kingdom

Investor stats

  • Total investments: 2
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
  • Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Show all investments...

David Rowan
Angel · London, England, United Kingdom · 1 investments in United Kingdom Biotechnology startups

David Rowan is editor of the UK edition of WIRED magazine, which won 2009 Launch of the David Rowan is Editor of the WIRED UK, the technology and trends magazine covering online brands, gadgets and the culture that surrounds them. David has reported on technology for The Times and Channel 4 News, the latter requiring him to illustrate the newiPod Video from the set of a porn shoot. He's also written for The Sunday Times and Telegraph Magazines, and edited the Guardian's on-line content. David has curated an exhibition of British creative talent at the Government's Cabinet Forum conference. He has also addressed the TEDs, and frequently contributes on Newsnight and the Today programme. He also writes a monthly column for GQ. David is in touch with many of the world's leading trend-setters and spotters. In presentations he looks at how the net is disrupting almost every sector, how apps change consumer behaviour and why 'social commerce' is killing traditional marketing. He reveals the 10 trends that will change your market in the next decade - and what you should be doing now to protect yourself.

Show more...

Investment focus

  • Industry: Software, Artificial Intelligence, Information Technology
  • Stage:Seed, Pre-Seed
  • Geography: United Kingdom, Croatia, United States

Investor stats

  • Total investments: 22
  • Round size: Seed $1M–$2.4M
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • EWOR — Build a successful company with EWOR
  • Climate X — Climate X combines climate science and econometrics to deliver precise climate risk data without any black boxes.
  • Rhizocore Technologies — We develop high-performance strains of locally-sourced mycorrhizal fungi to improve tree growth, tree health and tree resiliency. We offer a sustainable solution to increase forest yields whilst improving the ability of trees to sequester carbon.
Show all investments...

Martin Chavez
Angel · New York, New York, United States · 1 investments in United Kingdom Biotechnology startups

Marty Chavez is executive vice president and chief financial officer of The Goldman Sachs Group, Inc. He is a member of the Management Committee, Firmwide Capital Committee, Firmwide Risk Committee and Steering Committee on Regulatory Reform. Marty is also a member of the Firmwide Hispanic/Latino Network and the Lesbian, Gay, Bisexual andTransgender Network.Marty first joined Goldman Sachs in 1993 in the J. Aron Currency and Commodities Division, where he was a senior energy strat until 1997. He returned to the firm as a managing director in Investment Banking Division Strats in 2005, becoming global co-head of Securities Division Strats and then global co-chief operating officer of the Equities Franchise. Prior to assuming his current role, Marty was chief information officer, responsible for the Technology Division and jointly responsible with divisional leadership for the firm’s global strategists. He was named partner in 2006.Prior to first joining the firm, Marty was co-founder and chief technology officer of Quorum Software Systems from 1989 to 1993. From 1997 to 2000, he was global head of energy derivatives at Credit Suisse Financial Products. In 2000, Marty co-founded Kiodex, Inc. and was chairman and chief executive officer until 2004.Marty serves on the Harvard Board of Overseers and is a Fellow of the New York Academy of Medicine.Marty earned a PhD in Medical Information Sciences from Stanford University in 1990, an SM in Computer Science from Harvard University in 1985, and an AB, magna cum laude, in Biochemical Sciences from Harvard College in 1985.

Show more...

Investment focus

  • Industry: Health Care, Machine Learning, Biotechnology
  • Stage:Series A, Seed, Private Equity
  • Geography: United States, United Kingdom

Investor stats

  • Total investments: 12
  • Lead/follow: 8% lead, 92% follow

Portfolio highlights

  • Hebbia — Hebbia's neural search lets you execute research 10X faster and 10X more accurately. Transform your productivity today.
  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
  • VMind AI — VMind is a frontier technology company building artificial general intelligence (AGI).
Show all investments...

Karl Wills
Angel · 1 investments in United Kingdom Biotechnology startups

Originally at MetaPack in 2000, Karl returned in November 2009 to take on the role as COO and CIO responsible for MetaPack’s Product Development, Support, Infrastructure and Carrier Integration. Karl is now responsible for handling MetaPack's legal activity and ensuring best practice is brought into all parts of the MetaPack operation toensure exceptional performance for our customers. In between the MetaPack roles, he worked for Abacus Billing as CEO before its sale to Mind CTI, successfully managing the company turnaround at Solution 1 as COO and interim CEO where he focused on improving their delivery function as well as their IT infrastructure.Prior to joining MetaPack that he has held roles such as Senior Supply Chain Director for EMI Records (based in The Netherlands), IT Director for EMI Operations and IT Director EMI France as well as a number of other UK and European IT and Logistics roles. This provides Karl with over 30 years experience in general management and the IT, logistics and warehouse industry.

Show more...

Investment focus

  • Industry: CRM, Farming, Agriculture
  • Stage:Seed
  • Geography: United Kingdom

Investor stats

  • Total investments: 1
  • Lead/follow: 0% lead, 100% follow

Portfolio highlights

  • Bionema — Leading UK biopesticides technology developer, specialising in organic chemical-free, biological crop protection for safe and sustainable agriculture.
Show all investments...

Chris Paul
Angel · 1 investments in United Kingdom Biotechnology startups

Christopher Emmanuel Paul is an American professional basketball player for the Oklahoma City Thunder of the National Basketball Association.

Show more...

Investment focus

  • Industry: Food and Beverage, Sports, Health Care
  • Stage:Seed, Series A
  • Geography: United States, France, Portugal

Investor stats

  • Total investments: 18
  • Lead/follow: 17% lead, 83% follow

Portfolio highlights

  • Scout - Make Money Moves — Our mission is to make investing fun, relatable, and safe. Scout is an investing platform that allows you to build investment portfolios aligned with your interests. Think: eco-friendly brands, Women-led companies, Bitcoin, and the most popular Gen Z stocks. With Scout, you choose what you invest in, and we risk-manage your portfolio so you caninvest safely.
  • Buoy — Zero sugar liquid electrolytes and ionic trace minerals that blend with any beverage, even alcohol and coffee. No sugar, no stevia, no dextrose, no flavorings and no artificial ingredients. Gluten and major allergen free. Vegan and non-GMO.
  • Mitchell & Ness — Mitchell & Ness Nostalgia manufactures and retails apparel and accessories for men and women. It focuses on offering consumers a range of licensed apparel from the NFL, NBA, NHL, and AFL; and non-licensed active wear. The company offers adjustables, banners and pennants, bottoms, buckets, fitted products, fleece products, jerseys, outerwear,shirts, slouch products, snapback products, and strapback products; and headwear, duffle bags, gloves, scarves, and socks.
Show all investments...

Biotechnology Angel investor funding in United Kingdom at a glance

Stats across 121 deals from 139 investors.

139
investors
in United Kingdom Biotechnology startups
121
deals
in United Kingdom Biotechnology startups
$2M
median round
in United Kingdom Biotechnology startups
6%
lead investors
lead at least one round
46%
Seed
most common funding stage

Access all 139 angel investors in United Kingdom Biotechnology startups.

Open List

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology Angel Investors in United Kingdom investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 139 angel investors investing in United Kingdom Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists

Broader lists